223 related articles for article (PubMed ID: 37006073)
1. A dose escalated fiducial marker-based image guided radical radiotherapy in locally advanced prostate cancers: A single institute experience from India.
Gupta PK; Rastogi N; Maria Das KJ; Kumar S
J Cancer Res Ther; 2023; 19(2):382-388. PubMed ID: 37006073
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.
Takeda K; Takai Y; Narazaki K; Mitsuya M; Umezawa R; Kadoya N; Fujita Y; Sugawara T; Kubozono M; Shimizu E; Abe K; Shirata Y; Ishikawa Y; Yamamoto T; Kozumi M; Dobashi S; Matsushita H; Chida K; Ishidoya S; Arai Y; Jingu K; Yamada S
Radiat Oncol; 2012 Jul; 7():105. PubMed ID: 22770471
[TBL] [Abstract][Full Text] [Related]
3. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.
Zelefsky MJ; Kollmeier M; Cox B; Fidaleo A; Sperling D; Pei X; Carver B; Coleman J; Lovelock M; Hunt M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):125-9. PubMed ID: 22330997
[TBL] [Abstract][Full Text] [Related]
4. Intensity-modulated radiotherapy (IMRT) to prostate and pelvic nodes-is pelvic lymph node coverage adequate with fiducial-based image-guided radiotherapy?
Eminowicz G; Dean C; Shoffren O; Macdougall N; Wells P; Muirhead R
Br J Radiol; 2014 May; 87(1037):20130696. PubMed ID: 24646126
[TBL] [Abstract][Full Text] [Related]
5. Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy.
Barelkowski T; Wust P; Kaul D; Zschaeck S; Wlodarczyk W; Budach V; Ghadjar P; Beck M
Strahlenther Onkol; 2020 Mar; 196(3):229-242. PubMed ID: 31873779
[TBL] [Abstract][Full Text] [Related]
6. Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance.
Nakamura K; Mizowaki T; Inokuchi H; Ikeda I; Inoue T; Kamba T; Ogawa O; Hiraoka M
Int J Clin Oncol; 2018 Feb; 23(1):158-164. PubMed ID: 28756594
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
[TBL] [Abstract][Full Text] [Related]
8. Image-guided intensity-modulated radiotherapy of prostate cancer: Analysis of interfractional errors and acute toxicity.
Rudat V; Nour A; Hammoud M; Alaradi A; Mohammed A
Strahlenther Onkol; 2016 Feb; 192(2):109-17. PubMed ID: 26545764
[TBL] [Abstract][Full Text] [Related]
9. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.
Zapatero A; Roch M; Büchser D; Castro P; Fernández-Banda L; Pozo G; Liñán O; Martin de Vidales C; Cruz-Conde A; García-Vicente F
Clin Transl Oncol; 2017 Sep; 19(9):1161-1167. PubMed ID: 28374321
[TBL] [Abstract][Full Text] [Related]
10. MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.
Zapatero A; Roch M; Castro Tejero P; Büchser D; Martin de Vidales C; González S; Rodríguez P; San Jose LA; Celada G; Murillo MT
Br J Radiol; 2022 Mar; 95(1131):20210683. PubMed ID: 34538073
[TBL] [Abstract][Full Text] [Related]
11. A comparison of treatment outcome between fiducial-based and bone-based image guided radiotherapy in prostate cancer patients.
Napieralska A; Majewski W; Kulik R; Głowacki G; Miszczyk L
Radiat Oncol; 2018 Nov; 13(1):235. PubMed ID: 30482212
[TBL] [Abstract][Full Text] [Related]
12. Image guided dose escalated prostate radiotherapy: still room to improve.
Martin JM; Bayley A; Bristow R; Chung P; Gospodarowicz M; Menard C; Milosevic M; Rosewall T; Warde PR; Catton CN
Radiat Oncol; 2009 Nov; 4():50. PubMed ID: 19887007
[TBL] [Abstract][Full Text] [Related]
13. Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients.
Marina O; Gustafson GS; Kestin LL; Brabbins DS; Chen PY; Ye H; Martinez AA; Ghilezan MI; Wallace M; Krauss DJ
Brachytherapy; 2014; 13(1):59-67. PubMed ID: 23871661
[TBL] [Abstract][Full Text] [Related]
14. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance.
Sveistrup J; af Rosenschöld PM; Deasy JO; Oh JH; Pommer T; Petersen PM; Engelholm SA
Radiat Oncol; 2014 Feb; 9():44. PubMed ID: 24495815
[TBL] [Abstract][Full Text] [Related]
15. Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer.
Vesprini D; Catton C; Jacks L; Lockwood G; Rosewall T; Bayley A; Chung P; Gospodarowicz M; Ménard C; Milosevic M; Nichol A; Skala M; Warde P; Bristow RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):608-16. PubMed ID: 22099034
[TBL] [Abstract][Full Text] [Related]
16. PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two years.
Shakespeare TP; Eggert E; Wood M; Westhuyzen J; Turnbull K; Rutherford N; Aherne N
Radiother Oncol; 2019 Dec; 141():188-191. PubMed ID: 31668514
[TBL] [Abstract][Full Text] [Related]
17. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.
Murray J; Griffin C; Gulliford S; Syndikus I; Staffurth J; Panades M; Scrase C; Parker C; Khoo V; Dean J; Mayles H; Mayles P; Thomas S; Naismith O; Baker A; Mossop H; Cruickshank C; Hall E; Dearnaley D;
Radiother Oncol; 2020 Jan; 142():62-71. PubMed ID: 31767473
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
Adkison JB; McHaffie DR; Bentzen SM; Patel RR; Khuntia D; Petereit DG; Hong TS; Tomé W; Ritter MA
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):184-90. PubMed ID: 21163590
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
20. Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer.
Bayley A; Rosewall T; Craig T; Bristow R; Chung P; Gospodarowicz M; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):477-83. PubMed ID: 19733014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
